

# Uterine Leiomyomata with Liver Metastasis: A Case Report

*by* Jana Publication & Research

---

**Submission date:** 23-Aug-2025 12:28PM (UTC+0700)

**Submission ID:** 2690355736

**File name:** IJAR-53505.docx (20.33K)

**Word count:** 1274

**Character count:** 7587

## Uterine Leiomyomata with Liver Metastasis: A Case Report

### Introduction:

Leiomyomas are the most common benign monoclonal neoplasm of smooth muscle cells of uterus. The incidence increases with age, 4.3 per 1000 women years for 25-29 years old and 22.5 for 40-44 years old. Leiomyomata presents as abnormal uterine bleeding, pelvic pain, back pain, urinary symptoms. The different variants are: mitotically active leiomyoma, cellular leiomyoma, leiomyoma with bizarre nuclei (also called atypical or symplastic), smooth muscle tumor of uncertain malignant potential (STUMP), while the malignant variants are the Leiomyosarcoma (LMSs). LMS arises from smooth muscle cells or from precursor mesenchymal stem cells. The peak incidence of uLMS occurs in perimenopausal age group but can also start after the third decade of life. About 3-7% of all uterine malignancies are uterine sarcoma and in uterine sarcomas LMS accounts for 80% [1]. uLMS presents with abnormal vaginal bleeding, pelvic mass, pain in abdomen, rapidly growing uterine mass in post menopausal women, average diameter is 10 cm. Most common site is uterine corpus, rarely cervix.

Suspicion of uLMS should be there if MRI features suggest (a) high signals in T2W1 and abnormal signals in DWI (b) high signal in T1W1 (c) ill defined border of tumor mass with high cell density in mass, suggesting hemorrhage within the mass and infiltrative growth of mass.

Gross description represents often a solitary, fleshy, bulky mass within the myometrium. Histopathology represents spindle cell type, marked cytological atypia,  $\geq 10$  mitosis/10 high power fields, tumor cell necrosis.

### Case presentation:

A young nulliparous woman in late thirties, was referred to our hospital with heavy menstrual bleeding, abdominal pain associated with an abdominal mass. Her Eastern Cooperative Oncology Group (ECOG) performance status was I, she was pale with a hemoglobin 7 gm/dl for which 3 units of blood were transfused, her breast examination was normal. On abdominal examination - a mass arising from pelvis of approximately 15 x 15 cm which was well defined, tender and ballotable sideways, was palpable. Pelvic examination revealed a uniformly enlarged uterus with a well-defined smooth surfaced mass which was palpated through the posterior fornix, inseparable from the uterus, probably arising from posterior part of fundus.

Abdominal ultrasound revealed bulky uterus with uterine fibroid (10 x 7.6 x 7.3 cm). Contrast enhanced computed tomography of the whole abdomen revealed an enlarged anteverted uterus, with heterogeneous lesion (8.2 x 8.4 x 7.1 cm) in posterior myometrium causing displacement and compression of endometrial stripe. A smaller peripherally enhancing focal lesion of 2 x 1.3 cm seen in anterior aspect of fundus. The anterior surface of fundus of uterus was abutting rectum. The lesion was causing mass effect by displacing adjacent bowel loops. Liver was normal size. Multiple non enhancing discrete variable size (12.7 x 13 mm) hypodense lesions seen in both lobes of liver suggestive of metastasis. (Fig 1) Few discrete sub-

centimetric lymph nodes were seen in para-aortic region- 9 x 5mm. There was no history of radiation exposure, genetic (cancers or others) syndrome running in family, no history of early menarche and no history of tobacco or alcohol use.

Endometrial tissue was sampled and it was secretory with no other pathology identified, while the liver and uterine mass biopsy were inconclusive. Since the patient was deemed operable, therefore, an exploratory laparotomy was planned suspecting leiomyosarcoma. **Laparotomy findings:** Total abdominal hysterectomy with bilateral salpingo-oophorectomy was performed. Liver surface was studded with firm nodules that were biopsied. There were few deposits in pelvic peritoneum and pouch of Douglas while rest of the peritoneal cavity was normal. Final histopathology was suggestive of leiomyomata in the uterus and dissemination in pelvis and liver. The patient has been on follow-up with ultrasound of abdomen and liver performed every 3-6 months ever since and has completed 2 years uneventfully. No estrogen-based HRT was given however tibolone 2.5 mg was given for 2 years and the patient remained symptom free. The liver deposits decreased in size and have been stable ever since.

#### Discussion:

Uterine leiomyoma are the most common, solid, and benign monoclonal tumours of smooth muscle cells of the myometrium composed of extracellular matrix containing collagen, fibronectin, and proteoglycan and affecting 20% to 30% of women in their reproductive ages. Clinical symptoms occur in approximately 20%–30% of women who are older than 35 years. About 60% of tumours are multiple as was seen in our patient. Symptoms include abdominal pain, abnormal uterine bleeding, infertility, constipation, urinary problems. Our patient presented with prolonged heavy bleeding. Multiple and huge masses can get degenerations like hyaline, cystic, myxoid, atypical due to insufficient distribution of blood and therefore may not be discernible separate from malignant masses. Leiomyosarcoma can sometimes mimic leiomyomas. Brohl et al. concluded that sarcomas are diagnosed in presumed fibroids after surgery in 1 in 340 women. That number increases to 1 in 98 in women 75 to 79 years of age. [2]

While deciding on treatment, the patient's age, presenting symptoms, and desire for fertility preservation all merit consideration. The locations and size of the leiomyomata will both determine the treatment. Leiomyomatosis peritonealis disseminata (LPD) first introduced by Wilson et al in 1952, is a rare entity which is characterized by the presence of multiple subperitoneal or peritoneal smooth muscle nodules mimicking a malignant process. [3] The disease's asymptomatic nature may explain the disease's underestimated incidence of 1/1000000 [4]. It has been proposed that LPD arises under the influence of estrogen, metaplasia and differentiation of mesenchymal stem cells into smooth muscle cells occurs. Therefore, LPD is often considered a premenopausal benign disease.

Patients are often asymptomatic or present as symptoms such as abdominal pain and discomfort, and irregular vaginal bleeding, hence, pre operative diagnosis of LPD is difficult. It is sometimes difficult to differentiate LPD from malignancy due to raised serum CA 125 and disseminated presentation.

Ultrasonography, CT, and MRI are among the most effective diagnostic methods, but they are also not

effective in the differentiating from malignancies. In our patient CA 125 was not raised and CT scan could not differentiate between fibroid and sarcoma. MRI could not be done owing to logistic reasons. Histopathologic examination confirms the diagnosis of LPD. For women who do not desire fertility, a more extensive surgical approach with total abdominal hysterectomy, salpingo-oophorectomy, and debulking is done. Reported recurrence interval from 7 months to 8 years indicate that surveillance should take place for at least 3 years post initial resection. Liver metastasis is not a common presentation and conservative management may be effective as observed in this patient.

#### Conclusion:

Leiomyomatosis is a rare entity with no specific diagnostic criteria for confirmation of diagnosis clinically. They are often diagnosed postoperatively in patients operated for fibroids. Liver metastasis can be a rare presentation and may be managed without any active surgical or medical intervention.

#### Learning Points:

- LPD should be considered as differential diagnosis in patients who are presented with appearance of disseminated malignancy with uterine masses suggestive of fibroids.
- Follow up through imaging preferably through ultrasonography should be done for at least 3 years.
- Leiomyosarcoma should be suspected in peri or post-menopausal women, while leiomyomatosis usually occurs in the reproductive age group.

**References:**

1. Cui RR, Wright JD, Hou JY. Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome. *BJOG*. 2017 Jun;124(7):1028-1037. doi: 10.1111/1471-0528.14579. Epub 2017 Apr 1. PMID: 28128524.
2. Brohl AS, Li L, Andikyan V, Običan SG, Cioffi A, Hao K, Dudley JT, Ascher-Walsh C, Kasarskis A, Maki RG. Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. *Oncologist*. 2015 Apr;20(4):433-9.
3. Tun AM, Tun NM, Zin Thein K, Naing EE, Giashuddin S, Shulimovich M. A Rare Concurrence of Leiomyomatosis Peritonealis Disseminata, Leiomyosarcoma of the Pelvis and Leiomyomatous Nodule of the Liver. *Case Rep Oncol Med*. 2016;2016:3025432. doi: 10.1155/2016/3025432. Epub 2016 Feb 22. PMID: 26998373; PMCID: PMC4779833.
4. S Rezai, A Hughes, J Ligorski Disseminated peritoneal leiomyomatosis (DPL); a case report and review of literature *ObstetGynecol Int J*, 7 (2) (2017), p. 00240, [10.15406/ogij.2017.07.00240](https://doi.org/10.15406/ogij.2017.07.00240)

# Uterine Leiomyomata with Liver Metastasis: A Case Report

## ORIGINALITY REPORT

23%

SIMILARITY INDEX

14%

INTERNET SOURCES

17%

PUBLICATIONS

4%

STUDENT PAPERS

## PRIMARY SOURCES

1

Lei Yang, Na Liu, Yun Liu. "Leiomyomatosis peritonealis disseminata", Medicine, 2020

Publication

6%

2

[www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)

Internet Source

6%

3

Submitted to National postgraduate Medical College of Nigeria

Student Paper

2%

4

[ijrcog.org](http://ijrcog.org)

Internet Source

2%

5

Zineb Izi, Mustapha Outznit, Amine Cherraji, Mohammed Tbouda, Nabil Moatassim Billah, Ittimade Nassar. "Disseminated peritoneal leiomyomatosis: A case report", Radiology Case Reports, 2023

Publication

1%

6

[pubmed.ncbi.nlm.nih.gov](http://pubmed.ncbi.nlm.nih.gov)

Internet Source

1%

7

A. Romano Cardozo, M.A. Molina Pérez, J. Navarro Keller, C. Reyes Moncayo et al. "72P Thrombosis in leiomyosarcoma: Characteristics, assessment of predictive scores and survival analysis", ESMO Open, 2024

Publication

1%

|    |  |     |
|----|--|-----|
| 8  | Abdominal Imaging, 2013.<br>Publication  | 1 % |
| 9  | triarte.brynmawr.edu<br>Internet Source  | 1 % |
| 10 | www.dovepress.com<br>Internet Source   | 1 % |
| 11 | Keisuke Kodama, Kenzo Sonoda, Masako Kijima, Shinichiro Yamaguchi et al.<br>"Retrospective analysis of treatment and prognosis for uterine leiomyosarcoma: 10-year experience of a single institute", Asia-Pacific Journal of Clinical Oncology, 2020<br>Publication | 1 % |
| 12 | impactfactor.org<br>Internet Source  | 1 % |
| 13 | pmc.ncbi.nlm.nih.gov<br>Internet Source  | 1 % |
| 14 | RR Cui, JD Wright, JY Hou. "Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome", BJOG: An International Journal of Obstetrics & Gynaecology, 2017<br>Publication  | 1 % |

Exclude quotes On

Exclude matches Off

Exclude bibliography On